Updates from ImmunoMet

For investor enquiries, partnership discussions, or clinical questions, use the form below and the relevant team member will respond.

Clinical Data Presented at Major Oncology Conferences

January 2025 · San Francisco

ASCO GI 2025

Phase 1b/2a interim data for lixumistat in advanced pancreatic cancer presented at the ASCO Gastrointestinal Cancers Symposium.

CONFERENCE PRESENTATION

July 2025 · Barcelona

ESMO GI 2025

Updated Phase 1b/2a PDAC data presented at the ESMO Gastrointestinal Cancers Symposium.

CONFERENCE PRESENTATION

une 22–25, 2026 · San Diego

BIO International 2026

ImmunoMet presenting updated data and investment thesis at BIO International 2026, San Diego Convention Center.

UPCOMING

Peer-reviewed Research

2022 · Investigational New Drugs

Janku et al. — Phase 1 dose escalation study of lixumistat

Published results of the completed Phase 1 study (NCT03272256) in patients with advanced solid tumours. Safety profile established. No dose-limiting toxicities.

Publication

In Progress

Phase 1b/2a PDAC interim publication

Interim data from the ongoing PDAC trial at MD Anderson. Publication in progress as confirmed in investor slides.

Upcoming

Additional publications TBC

Additional references

Dean to provide any additional publications or references to include on this page.

TBC

Janku et al. 2022 confirmed from investor deck. Phase 1b/2a publication "in progress" confirmed from ImmunoMet_Investor_Slides_202603_1.pdf. Additional publications to be provided by Dean.